Do you want to read an article? Please log in or register.
Modest reduction in the risk of obesity-related cancers with GLP-1 receptor agonists
Further Publications
CHICAGO 2025
Related content
Lung, Respiratory and Thoracic Cancer
Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study
Lung Cancer
Tafur A, Sebai A, Shi Z, Wei J, Tran H, Zheng SL, Krantz S, Hensing T, Mansfield AS, Xu J
doi: 10.1016/j.lungcan.2025.108712
Breast Cancer
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
J Clin Oncol
Hurvitz SA, Layman RM, Curigliano G, André F, Cristofanilli M, Kim SB, Martínez Rodríguez JL, Nadal JC, Kim GM, Lo L, Remolina-Bonilla YA, Rosselli G, Emile G, Korbenfeld E, Puig JM, Wesolowski R, Martin M, Ring A, Han HS, Giordano A, Mutka SC, Moss K, Suzuki S, Sullivan B, Gorbatchevsky I, Pistilli B, VIKTORIA-1 Study Group
doi: 10.1200/JCO-25-02643
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Genitourinary Cancer
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
JAMA Oncol
Patel NA, Barocas DA, Lin DW, Wu X, Green D, Kensler KH, Shoag J, Al Hussein Al Awamlh B
doi: 10.1001/jamaoncol.2025.2304
Further Publications
Assessing quality of life in individuals with hereditary cancer risk: Results from phases 1-3a of the EORTC QLQ-HCR30 questionnaire
Eur J Cancer
Engele VI, Vassiliou V, Wheelwright S, Sztankay M, Puglisi C, Pogoda K, van Leeuwaarde R, Bleiker E, Abdel-Razeq H, Fox L, Lanceley A, Dabakuyo S, Bjelic-Radisic V, Nordin A, Ioannidis G, Kulís D, Brédart A, Schwaninger G, Arraras JI, Holzner B, Oberguggenberger AS, EORTC Quality of Life Group
doi: 10.1016/j.ejca.2026.116226
RECOMMENDED
Breast Cancer
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
J Clin Oncol
Valenza C, Zheng Y, Milano M, Trapani D, Giordano E, Guidi L, Berton Giachetti PPM, Boldrini L, Castellano G, Katrini J, Malagutti B, Antonarelli G, Conforti F, Pagan E, Bagnardi V, Kirkner GJ, Sangalli C, Dibble KE, Colleoni M, Regan MM, Munzone E, Curigliano G, Partridge AH
doi: 10.1200/JCO-25-01660
Genitourinary Cancer
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
Ann Oncol
Jones C, Dutey-Magni P, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, Parmar MKB, Attard G, Sydes MR, Brown LC, James ND, Clarke NW, Sachdeva A, STAMPEDE Trial Investigators
doi: 10.1016/j.annonc.2025.07.005
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
Further Publications
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations
J Clin Oncol
Sicklick JK, Nishizaki D, Miyashita H, Okamura R, Hahn ME, Nikanjam M, Fanta PT, Piccioni DE, Patel H, Eskander RN, McKay RR, Ross JS, Lee JJ, Lippman SM, Kato S, Kurzrock R
doi: 10.1200/JCO-25-01453